Clinical Trial Detail

NCT ID NCT02457910
Title Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Enzalutamide

Enzalutamide + Taselisib

Age Groups: adult senior

Additional content available in CKB BOOST